Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.
Portfolio Pulse from Benzinga Newsdesk
Mesoblast shares are trading higher after the company announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.
July 23, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mesoblast shares are trading higher after the FDA accepted its Biologics License Application resubmission for Ryoncil, aimed at treating children with steroid-refractory acute graft versus host disease.
The acceptance of the Biologics License Application by the FDA is a significant regulatory milestone for Mesoblast. This development increases the likelihood of Ryoncil reaching the market, which could lead to higher revenues and improved investor sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100